Jul 25, 2021 / 03:30PM GMT
Presentation
Jul 25, 2021 / 03:30PM GMT
=====================
Corporate Participants
=====================
* Carole Ho
Denali Therapeutics Inc. - Chief Medical Officer & Head of Development
* Laura Hansen
Denali Therapeutics Inc. - VP of IR
* Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director
=====================
Laura Hansen - Denali Therapeutics Inc. - VP of IR
Hello, and welcome to the Denali Therapeutics webinar on interim data from our Phase I/II study of DNL310 in patients with Hunter syndrome or MPS II. I am Laura Hansen, Vice President of Investor Relations, and I'd like to thank you for joining our webcast today. Please note that the press release we issued earlier today and the slide deck for this webcast are available in the Investors section of our website, denalitherapeutics.com.
Before we get started, I'd like to note that the presentations given today and the responses to questions will contain forward-looking statements regarding Denali's future plans,
Denali Therapeutics Inc to Present Phase 1/2 Study of DNL310 Presentation Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot